文献速递胸部肿瘤

厄洛替尼联合贝伐珠单抗对比厄洛替尼单药治疗EGFR阳性晚期非鳞状非小细胞肺癌(NEJ026):开放标签、随机、多中心、3期试验的期中分析

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2019-04-08

NEJ026研究为开放标签、随机、多中心3期试验,纳入228例EGFR阳性晚期非鳞状非小细胞肺癌患者,随机接受厄洛替尼联合贝伐珠单抗或厄洛替尼单药治疗。期中分析显示联合组中位无进展生存期为16.9个月,单药组为13.3个月(HR 0.605,95%CI 0.417-0.877;p=0.016)。联合组3级及以上不良事件发生率为88%,单药组为46%。

要点

  • 联合组中位无进展生存期为16.9个月,单药组为13.3个月(HR 0.605,95%CI 0.417-0.877;p=0.016)。
  • 联合组98例(88%)发生3级及以上不良事件,单药组53例(46%)。
  • 无治疗相关死亡。

核心结论

  • 期中分析显示,在EGFR阳性非小细胞肺癌患者中,贝伐珠单抗联合厄洛替尼较厄洛替尼单药改善无进展生存期。
  • 需要更长期随访以及总生存和生活质量数据来进一步评估该联合方案在此背景下的疗效。

研究设计与样本

  • 随机、开放标签、3期NEJ026试验的预设期中分析,在日本69个中心招募患者。
  • 纳入标准:IIIB-IV期或复发、细胞学或组织学确认的非鳞状非小细胞肺癌,具有激活EGFR基因组变异,年龄至少20岁,ECOG体能状态评分2或以下,未接受过晚期疾病化疗,至少一个可测量病灶(RECIST 1.1)。
  • 按1:1随机分配至口服厄洛替尼150 mg/日联合静脉贝伐珠单抗15 mg/kg每21天一次,或厄洛替尼150 mg/日单药;随机化采用最小化法,按性别、吸烟状态、临床分期和EGFR突变亚型分层。
  • 主要终点为无进展生存期;数据截止日期为2017年9月21日。
  • 2015年6月3日至2016年8月31日期间,228例患者被随机分配至联合组(n=114)或单药组(n=114);每组112例可评估疗效;安全性分析联合组112例、单药组114例。

主要发现

  • 联合组中位无进展生存期为16.9个月(95%CI 14.2-21.0),单药组为13.3个月(95%CI 11.1-15.3),风险比HR 0.605(95%CI 0.417-0.877;p=0.016)。
  • 联合组112例中98例(88%)发生3级或更差不良事件,单药组114例中53例(46%)。
  • 最常见的3-4级不良事件为皮疹:联合组112例中23例(21%),单药组114例中24例(21%)。
  • 联合组112例中9例(8%)发生严重不良事件,单药组114例中5例(4%)。
  • 最常见的严重不良事件为4级中性粒细胞减少(联合组112例中2例[2%])和4级肝功能障碍(联合组112例中1例[1%],单药组114例中1例[1%]);无治疗相关死亡。

关键数值与推荐

  • 联合组中位无进展生存期16.9个月(95%CI 14.2-21.0)vs 单药组13.3个月(95%CI 11.1-15.3),HR 0.605(95%CI 0.417-0.877;p=0.016)。
  • 联合组3级及以上不良事件98/112例(88%)vs 单药组53/114例(46%)。
  • 联合组严重不良事件9/112例(8%)vs 单药组5/114例(4%)。

局限性

  • 原文报告为预设期中分析,中位随访时间为12.4个月(IQR 7.0-15.7)。
  • 原文结论指出需要更长期随访以及总生存和生活质量数据来进一步评估该联合方案的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Resistance to first-generation or second-generation EGFR tyrosine kinase inhibitor (TKI) monotherapy develops in almost half of patients with EGFR-positive non-small-cell lung cancer (NSCLC) after 1 year of treatment. The JO25567 phase 2 trial comparing erlotinib plus bevacizumab combination therapy with erlotinib monotherapy established the activity and manageable toxicity of erlotinib plus bevacizumab in patients with NSCLC. We did a phase 3 trial to validate the results of the JO25567 study and report here the results from the preplanned interim analysis. METHODS: In this prespecified interim analysis of the randomised, open-label, phase 3 NEJ026 trial, we recruited patients with stage IIIB-IV disease or recurrent, cytologically or histologically confirmed non-squamous NSCLC with activating EGFR genomic aberrations from 69 centres across Japan. Eligible patients were at least 20 years old, and had an Eastern Cooperative Oncology Group performance status of 2 or lower, no previous chemotherapy for advanced disease, and one or more measurable lesions based on Response Evaluation Criteria in Solid Tumours (1.1). Patients were randomly assigned (1:1) to receive oral erlotinib 150 mg per day plus intravenous bevacizumab 15 mg/kg once every 21 days, or erlotinib 150 mg per day monotherapy. Randomisation was done by minimisation, stratified by sex, smoking status, clinical stage, and EGFR mutation subtype. The primary endpoint was progression-free survival. This study is ongoing; the data cutoff for this prespecified interim analysis was Sept 21, 2017. Efficacy was analysed in the modified intention-to-treat population, which included all randomly assigned patients who received at least one dose of treatment and had at least one response evaluation. Safety was analysed in all patients who received at least one dose of study drug. The trial is registered with the University Hospital Medical Information Network Clinical Trials Registry, number UMIN000017069. FINDINGS: Between June 3, 2015, and Aug 31, 2016, 228 patients were randomly assigned to receive erlotinib plus bevacizumab (n=114) or erlotinib alone (n=114). 112 patients in each group were evaluable for efficacy, and safety was evaluated in 112 patients in the combination therapy group and 114 in the monotherapy group. Median follow-up was 12·4 months (IQR 7·0-15·7). At the time of interim analysis, median progression-free survival for patients in the erlotinib plus bevacizumab group was 16·9 months (95% CI 14·2-21·0) compared with 13·3 months (11·1-15·3) for patients in the erlotinib group (hazard ratio 0·605, 95% CI 0·417-0·877; p=0·016). 98 (88%) of 112 patients in the erlotinib plus bevacizumab group and 53 (46%) of 114 patients in the erlotinib alone group had grade 3 or worse adverse events. The most common grade 3-4 adverse event was rash (23 [21%] of 112 patients in the erlotinib plus bevacizumab group vs 24 [21%] of 114 patients in the erlotinib alone group). Nine (8%) of 112 patients in the erlotinib plus bevacizumab group and five (4%) of 114 patients in the erlotinib alone group had serious adverse events. The most common serious adverse events were grade 4 neutropenia (two [2%] of 112 patients in the erlotinib plus bevacizumab group) and grade 4 hepatic dysfunction (one [1%] of 112 patients in the erlotinib plus bevacizumab group and one [1%] of 114 patients in the erlotinib alone group). No treatment-related deaths occurred. INTERPRETATION: The results of this interim analysis showed that bevacizumab plus erlotinib combination therapy improves progression-free survival compared with erlotinib alone in patients with EGFR-positive NSCLC. Future studies with longer follow-up, and overall survival and quality-of-life data will be required to further assess the efficacy of this combination in this setting. FUNDING: Chugai Pharmaceutical.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019. PMID: 30975627. doi:10.1016/S1470-2045(19)30035-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。